Bmi1 knockdown inhibits hepatocarcinogenesis

Ruan,Zhi-Ping; Xu,Rui; Lv,Yi; Tian,Tao; Wang,Wen-Juan; Guo,Hui; Nan,Ke-Jun

doi:10.3892/ijo.2012.1693

Bmi1 knockdown inhibits hepatocarcinogenesis

Authors:
- Zhi-Ping Ruan
- Rui Xu
- Yi Lv
- Tao Tian
- Wen-Juan Wang
- Hui Guo
- Ke-Jun Nan
View Affiliations

Affiliations: Department of Oncology, First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi’an, Shaanxi, P.R. China, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China, Department of Hepatobiliary Surgery, First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China
Published online on: November 9, 2012 https://doi.org/10.3892/ijo.2012.1693
Pages: 261-268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although Bmi1 is well established as one of the most commonly activated oncogenes, the precise role of Bmi1 during hepatocarcinogenesis remains unclear. In addition, Bmi1 provides a potential therapeutic target for the future treatment of hepatocellular carcinoma (HCC). In this study, the expression of Bmi1 in HCC tissues was evaluated by immunohistochemistry and western blot analysis. We found that Bmi1 was much more highly expressed in HCC tissue compared to normal liver tissue. The shRNA-mediated knockdown of Bmi1 was used to assess the effects of Bmi1 in hepatocarcinogenesis. Bmi1 downregulation reduced cell growth and tumorsphere formation in vitro. A cell cycle analysis using flow cytometry clarified that Bmi1 knockdown blocked the cell cycle transition from the G0/G1 to the S phase. Additionally, the Bmi1 knockdown led to reduced tumorigenicity in vivo. Furthermore, Bmi1 expression enhanced the sensitivity of HCC to the therapeutic agent, sorafenib. Taken together, the current results demonstrate that Bmi1 functions as a promoter in cell proliferation and hepatocarcinogenesis, providing a potential therapeutic target for the future treatment of HCC.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2.	Bertolini G, Roz L, Perego P, et al: Highly tumorigenic lung cancer CD133⁺ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 106:16281–16286. 2009.PubMed/NCBI
3.	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
4.	Uchida N, Buck DW, He D, et al: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA. 97:14720–14725. 2000. View Article : Google Scholar : PubMed/NCBI
5.	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Rountree CB, Ding W, He L and Stiles B: Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells. 27:290–299. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Van der Lugt NM, Domen J, Linders K, et al: Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 protooncogene. Genes Dev. 8:757–769. 1994.
9.	Pirrotta V: Polycombing the genome: PcG, trxG, and chromatin silencing. Cell. 93:333–336. 1998. View Article : Google Scholar : PubMed/NCBI
10.	Kranc KR, Bamforth SD, Braganca J, Norbury C, van Lohuizen M and Bhattacharya S: Transcriptional coactivator Cited2 induces Bmi1 and Mel18 and controls fibroblast proliferation via Ink4a/ARF. Mol Cell Biol. 23:7658–7666. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Saito M, Handa K, Kiyono T, et al: Immortalization of cementoblast progenitor cells with Bmi-1 and TERT. J Bone Miner Res. 20:50–57. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Kim JH, Yoon SY, Kim CN, et al: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 203:217–224. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Sasaki M, Ikeda H, Itatsu K, et al: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest. 88:873–882. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Vrzalikova K, Skarda J, Ehrmann J, et al: Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol. 134:1037–1042. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Park IK, Qian D, Kiel M, et al: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 423:302–305. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Lessard J and Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 423:255–260. 2003. View Article : Google Scholar : PubMed/NCBI
17.	Liu S, Dontu G, Mantle ID, et al: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66:6063–6071. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Chiba T, Seki A, Aoki R, et al: Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice. Hepatology. 52:1111–1123. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Glinsky GV: Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem Cell Rev. 3:79–93. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Wang H, Pan K, Zhang HK, et al: Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 134:535–541. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Zhang Y, Li B, Ji ZZ and Zheng PS: Notch1 regulates the growth of human colon cancers. Cancer. 116:5207–5218. 2010. View Article : Google Scholar : PubMed/NCBI
22.	Tomuleasa C, Soritau O, Rus-Ciuca D, et al: Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI
23.	Zhu Z, Hao X, Yan MX, et al: Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 126:2067–2078. 2010.
24.	Leung C, Lingbeek M, Shakhova O, et al: Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 428:337–341. 2004. View Article : Google Scholar : PubMed/NCBI
25.	Vonlanthen S, Heighway J, Altermatt HJ, et al: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Kim JH, Yoon SY, Jeong SH, et al: Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 13:383–388. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM and Glinsky GV: Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 5:1886–1901. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Qin ZK, Yang JA, Ye YL, et al: Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer. 9:612009. View Article : Google Scholar : PubMed/NCBI
29.	Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Chiba T, Miyagi S, Saraya A, et al: The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 68:7742–7749. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Cui H, Hu B, Li T, et al: Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol. 170:1370–1378. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Bruggeman SW, Hulsman D, Tanger E, et al: Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 12:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
33.	Yu CC, Lo WL, Chen YW, et al: Bmi-1 regulates Snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J Oncol. 2011:pii:. 6092592011.PubMed/NCBI
34.	Park IK, Morrison SJ and Clarke MF: Bmi1, stem cells, and senescence regulation. J Clin Invest. 113:175–179. 2004. View Article : Google Scholar : PubMed/NCBI
35.	Dimri GP, Martinez JL, Jacobs JJ, et al: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 62:4736–4745. 2002.PubMed/NCBI
36.	Jane EP, Premkumar DR and Pollack IF: Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 319:1070–1080. 2006. View Article : Google Scholar : PubMed/NCBI
37.	Yu C, Friday BB, Lai JP, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 5:2378–2387. 2006. View Article : Google Scholar